국소 진통제 시장 규모, 점유율, 동향 분석 보고서 : 약물 계열별, 통증별, 제형별, 처방별, 유통 채널별, 지역별 및 부문별 예측(2026-2033년)

Topical Analgesics Market Summary

The global topical analgesics market size was valued at USD 11.9 billion in 2025 and is projected to grow from USD 12.5 billion in 2026 to USD 18.6 billion by 2033, at a CAGR of 5.9% from 2026 to 2033. North America dominated the market, accounting for a revenue share of 41.2% in 2025. Growth in the market is supported by the increasing prevalence of chronic musculoskeletal disorders, osteoarthritis, rheumatoid arthritis, sports-related injuries, and an aging population requiring long-term pain management.

Rising preference for localized pain relief with redud systemic adverse effects compared to oral analgesics has contributed to broader product adoption. The expansion of OTC availability, improvements in transdermal drug delivery technologies, and the introduction of prescription-strength topical formulations have further strengthened market development. In addition, growing consumer awareness regarding self-care, increasing demand for non-opioid pain management options, and wider availability through retail pharmacies, e-commerce platforms, and hospital pharmacies continue to support product accessibility. Ongoing product innovation, including enhanced drug penetration technologies and long-acting topical formulations, is further contributing to market growth.

Market Concentration & Characteristics

The topical analgesics industry demonstrates a moderate-to-high degree of innovation driven by advancements in drug delivery systems, formulation technologies, and patient-friendly dosage forms. Manufacturers are introducing improved transdermal patches, fast-absorbing gels, sprays, creams, and roll-on formulations that enhance drug penetration and provide prolonged pain relief. Development activities are also focused on non-opioid therapies, combination formulations, and improved adhesive technologies for topical patches. Companies continue to expand both prescription and over-the-counter product portfolios to address musculoskeletal pain, arthritis, neuropathic pain, and sports injuries. While many active pharmaceutical ingredients such as diclofenac, lidocaine, capsaicin, and menthol are well established, formulation improvements and differentiated delivery technologies continue to support product innovation across the market.

Barriers to entry in the topical analgesics industry are moderate due to regulatory requirements, formulation expertise, and manufacturing standards. Companies must demonstrate product quality, stability, bioavailability, and safety before obtaining regulatory approval, particularly for prescription topical products. Development of effective transdermal delivery systems requires specialized research capabilities and manufacturing infrastructure. However, the availability of established active pharmaceutical ingredients and the presence of contract manufacturing organizations reduce development complexity for generic and over-the-counter products. Large pharmaceutical companies benefit from established distribution networks, regulatory experience, and brand recognition, while regional manufacturers continue to enter the market through generic formulations and private-label products.

Regulatory agencies play an important role in maintaining the safety, efficacy, and quality of topical analgesic products. Prescription formulations require extensive clinical and manufacturing documentation before approval, while over-the-counter products must comply with applicable monograph requirements or regulatory pathways in individual countries. Manufacturing facilities are required to meet Good Manufacturing Practice (GMP) standards, and manufacturers must comply with labeling, pharmacovigilance, and post-marketing surveillance requirements. Regulatory oversight also governs product claims, ingredient concentrations, and manufacturing consistency. Although regulatory compliance increases development timelines and costs, it supports product quality and strengthens confidence among healthcare professionals and consumers.

The topical analgesics industry faces a high level of product substitution due to the availability of multiple pain management alternatives. Patients frequently use oral NSAIDs, acetaminophen, opioids, corticosteroid injections, physical therapy, and complementary therapies depending on pain severity and clinical indication. Non-pharmacological approaches such as heat therapy, cold therapy, exercise programs, and rehabilitation services also compete with topical products. Within the topical segment itself, numerous creams, gels, sprays, patches, ointments, and counterirritant products containing different active ingredients provide additional substitution options. The wide availability of generic products further increases competition across both prescription and OTC categories.

Geographical expansion remains moderate to high as pharmaceutical companies continue to strengthen their presence across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Growth is supported by increasing awareness of localized pain management, expanding retail pharmacy networks, wider e-commerce availability, and improving healthcare access in emerging economies. Companies are introducing approved products into additional countries through regional partnerships, licensing agreements, and expanded distribution channels. Rising prevalence of musculoskeletal disorders, aging populations, and increasing demand for self-managed pain relief continue to support expansion opportunities. Local manufacturers are also broadening product availability by introducing cost-effective generic topical analgesics across developing healthcare markets.

Global Topical Analgesics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global topical analgesics market report based on drug class, pain, dosage form, distribution channel, prescription and region:

• Drug Class Outlook (Revenue, USD Billion, 2021 - 2033)
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
• Local Anesthetics
• Counterirritants
• Capsaicin-Based Analgesics
• Combination Topical Analgesics
• Pain Outlook (Revenue, USD Billion, 2021 - 2033)
• Nociceptive Pain
• Neuropathic Pain
• Mixed Pain
• Dosage Form Outlook (Revenue, USD Billion, 2021 - 2033)
• Creams
• Gels
• Ointments
• Patches
• Sprays
• Others
• Prescription Outlook (Revenue, USD Billion, 2021 - 2033)
• Over the Counter (OTC)
• Prescription (Rx)
• Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2033)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Supermarkets & Hypermarkets
• Regional Outlook (Revenue, USD Billion, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Drug Class
  • 1.2.2. Pain
  • 1.2.3. Dosage Form
  • 1.2.4. Prescription
  • 1.2.5. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Topical Analgesics Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Pricing Analysis

Chapter 4. Topical Analgesics Market: Drug Class Business Analysis

• 4.1. Drug Class Market Share, 2025 & 2033
• 4.2. Drug Class Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2021 to 2033 (USD Billion)
• 4.4. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
  • 4.4.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Market, 2021 - 2033 (USD Billion)
• 4.5. Local Anesthetics
  • 4.5.1. Local Anesthetics Market, 2021 - 2033 (USD Billion)
• 4.6. Counterirritants
  • 4.6.1. Counterirritants Market, 2021 - 2033 (USD Billion)
• 4.7. Capsaicin-Based Analgesics
  • 4.7.1. Capsaicin-Based Analgesics Market, 2021 - 2033 (USD Billion)
• 4.8. Combination Topical Analgesics
  • 4.8.1. Combination Topical Analgesics Market, 2021 - 2033 (USD Billion)

Chapter 5. Topical Analgesics Market: Pain Business Analysis

• 5.1. Pain Market Share, 2025 & 2033
• 5.2. Pain Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Pain, 2021 to 2033 (USD Billion)
• 5.4. Nociceptive Pain
  • 5.4.1. Nociceptive Pain Market, 2021 - 2033 (USD Billion)
• 5.5. Neuropathic Pain
  • 5.5.1. Neuropathic Pain Market, 2021 - 2033 (USD Billion)
• 5.6. Mixed Pain
  • 5.6.1. Mixed Pain Market, 2021 - 2033 (USD Billion)

Chapter 6. Topical Analgesics Market: Dosage Form Business Analysis

• 6.1. Dosage Form Market Share, 2025 & 2033
• 6.2. Dosage Form Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Dosage Form, 2021 to 2033 (USD Billion)
• 6.4. Creams
  • 6.4.1. Creams Market, 2021 - 2033 (USD Billion)
• 6.5. Gels
  • 6.5.1. Gels Market, 2021 - 2033 (USD Billion)
• 6.6. Ointments
  • 6.6.1. Ointments Market, 2021 - 2033 (USD Billion)
• 6.7. Patches
  • 6.7.1. Patches Market, 2021 - 2033 (USD Billion)
• 6.8. Sprays
  • 6.8.1. Sprays Market, 2021 - 2033 (USD Billion)
• 6.9. Others
  • 6.9.1. Others Market, 2021 - 2033 (USD Billion)

Chapter 7. Topical Analgesics Market: Prescription Business Analysis

• 7.1. Dosage Form Market Share, 2025 & 2033
• 7.2. Dosage Form Segment Dashboard
• 7.3. Market Size & Forecasts and Trend Analysis, by Dosage Form, 2021 to 2033 (USD Billion)
  • 7.3.1. Over the Counter (OTC)
  • 7.3.2. Over the Counter (OTC) Market, 2021 -2033 (USD Billion)
• 7.4. Prescription (Rx)
  • 7.4.1. Prescription (Rx) Market, 2021 - 2033 (USD Billion)

Chapter 8. Topical Analgesics Market: Distribution Channel Business Analysis

• 8.1. Dosage Form Market Share, 2025 & 2033
• 8.2. Dosage Form Segment Dashboard
• 8.3. Market Size & Forecasts and Trend Analysis, by Dosage Form, 2021 to 2033 (USD Billion)
• 8.4. Hospital Pharmacies
  • 8.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Billion)
• 8.5. Retail Pharmacies
  • 8.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Billion)
• 8.6. Online Pharmacies
  • 8.6.1. Online Pharmacies Market, 2021 - 2033 (USD Billion)
• 8.7. Supermarkets & Hypermarkets
  • 8.7.1. Supermarkets & Hypermarkets Market, 2021 - 2033 (USD Billion)

Chapter 9. Topical Analgesics Market: Regional Estimates & Trend Analysis

• 9.1. Regional Market Share Analysis, 2025 & 2033
• 9.2. Regional Market Dashboard
• 9.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
• 9.4. North America
  • 9.4.1. North America Topical Analgesics Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Billion)
  • 9.4.2. U.S.
    • 9.4.2.1. Key Country Dynamics
    • 9.4.2.2. Target Disease Prevalence
    • 9.4.2.3. Regulatory Framework
    • 9.4.2.4. Reimbursement Framework
    • 9.4.2.5. U.S. Topical Analgesics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 9.4.3. Canada
    • 9.4.3.1. Key Country Dynamics
    • 9.4.3.2. Target Disease Prevalence
    • 9.4.3.3. Regulatory Framework
    • 9.4.3.4. Reimbursement Framework
    • 9.4.3.5. Canada Topical Analgesics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 9.4.4. Mexico
    • 9.4.4.1. Key Country Dynamics
    • 9.4.4.2. Target Disease Prevalence
    • 9.4.4.3. Regulatory Framework
    • 9.4.4.4. Reimbursement Framework
    • 9.4.4.5. Mexico Topical Analgesics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 9.5. Europe
  • 9.5.1. Europe Topical Analgesics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 9.5.2. UK
    • 9.5.2.1. Key Country Dynamics
    • 9.5.2.2. Target Disease Prevalence
    • 9.5.2.3. Regulatory Framework
    • 9.5.2.4. Reimbursement Framework
    • 9.5.2.5. UK Topical Analgesics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 9.5.3. Germany
    • 9.5.3.1. Key Country Dynamics
    • 9.5.3.2. Target Disease Prevalence
    • 9.5.3.3. Regulatory Framework
    • 9.5.3.4. Reimbursement Framework
    • 9.5.3.5. Germany Topical Analgesics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 9.5.4. France
    • 9.5.4.1. Key Country Dynamics
    • 9.5.4.2. Target Disease Prevalence
    • 9.5.4.3. Regulatory Framework
    • 9.5.4.4. Reimbursement Framework
    • 9.5.4.5. France Topical Analgesics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 9.5.5. Italy
    • 9.5.5.1. Key Country Dynamics
    • 9.5.5.2. Target Disease Prevalence
    • 9.5.5.3. Regulatory Framework
    • 9.5.5.4. Reimbursement Framework
    • 9.5.5.5. Italy Topical Analgesics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 9.5.6. Spain
    • 9.5.6.1. Key Country Dynamics
    • 9.5.6.2. Target Disease Prevalence
    • 9.5.6.3. Regulatory Framework
    • 9.5.6.4. Reimbursement Framework
    • 9.5.6.5. Spain Topical Analgesics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 9.5.7. Denmark
    • 9.5.7.1. Key Country Dynamics
    • 9.5.7.2. Target Disease Prevalence
    • 9.5.7.3. Regulatory Framework
    • 9.5.7.4. Reimbursement Framework
    • 9.5.7.5. Denmark Topical Analgesics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 9.5.8. Sweden
    • 9.5.8.1. Key Country Dynamics
    • 9.5.8.2. Target Disease Prevalence
    • 9.5.8.3. Regulatory Framework
    • 9.5.8.4. Reimbursement Framework
    • 9.5.8.5. Sweden Topical Analgesics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 9.5.9. Norway
    • 9.5.9.1. Key Country Dynamics
    • 9.5.9.2. Target Disease Prevalence
    • 9.5.9.3. Regulatory Framework
    • 9.5.9.4. Reimbursement Framework
    • 9.5.9.5. Norway Topical Analgesics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 9.6. Asia Pacific
  • 9.6.1. Asia Pacific Topical Analgesics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 9.6.2. Japan
    • 9.6.2.1. Key Country Dynamics
    • 9.6.2.2. Target Disease Prevalence
    • 9.6.2.3. Regulatory Framework
    • 9.6.2.4. Reimbursement Framework
    • 9.6.2.5. Japan Topical Analgesics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 9.6.3. China
    • 9.6.3.1. Key Country Dynamics
    • 9.6.3.2. Target Disease Prevalence
    • 9.6.3.3. Regulatory Framework
    • 9.6.3.4. Reimbursement Framework
    • 9.6.3.5. China Topical Analgesics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 9.6.4. India
    • 9.6.4.1. Key Country Dynamics
    • 9.6.4.2. Target Disease Prevalence
    • 9.6.4.3. Regulatory Framework
    • 9.6.4.4. Reimbursement Framework
    • 9.6.4.5. India Topical Analgesics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 9.6.5. Australia
    • 9.6.5.1. Key Country Dynamics
    • 9.6.5.2. Target Disease Prevalence
    • 9.6.5.3. Regulatory Framework
    • 9.6.5.4. Reimbursement Framework
    • 9.6.5.5. Australia Topical Analgesics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 9.6.6. South Korea
    • 9.6.6.1. Key Country Dynamics
    • 9.6.6.2. Target Disease Prevalence
    • 9.6.6.3. Regulatory Framework
    • 9.6.6.4. Reimbursement Framework
    • 9.6.6.5. South Korea Topical Analgesics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 9.6.7. Thailand
    • 9.6.7.1. Key Country Dynamics
    • 9.6.7.2. Target Disease Prevalence
    • 9.6.7.3. Regulatory Framework
    • 9.6.7.4. Reimbursement Framework
    • 9.6.7.5. Thailand Topical Analgesics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 9.7. Latin America
  • 9.7.1. Latin America Topical Analgesics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 9.7.2. Brazil
    • 9.7.2.1. Key Country Dynamics
    • 9.7.2.2. Target Disease Prevalence
    • 9.7.2.3. Regulatory Framework
    • 9.7.2.4. Reimbursement Framework
    • 9.7.2.5. Brazil Topical Analgesics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 9.7.3. Argentina
    • 9.7.3.1. Key Country Dynamics
    • 9.7.3.2. Target Disease Prevalence
    • 9.7.3.3. Regulatory Framework
    • 9.7.3.4. Reimbursement Framework
    • 9.7.3.5. Argentina Topical Analgesics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 9.8. Middle East and Africa
  • 9.8.1. Middle East and Africa Topical Analgesics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 9.8.2. South Africa
    • 9.8.2.1. Key Country Dynamics
    • 9.8.2.2. Target Disease Prevalence
    • 9.8.2.3. Regulatory Framework
    • 9.8.2.4. Reimbursement Framework
    • 9.8.2.5. South Africa Topical Analgesics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 9.8.3. Saudi Arabia
    • 9.8.3.1. Key Country Dynamics
    • 9.8.3.2. Target Disease Prevalence
    • 9.8.3.3. Regulatory Framework
    • 9.8.3.4. Reimbursement Framework
    • 9.8.3.5. Saudi Arabia Topical Analgesics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 9.8.4. UAE
    • 9.8.4.1. Key Country Dynamics
    • 9.8.4.2. Target Disease Prevalence
    • 9.8.4.3. Regulatory Framework
    • 9.8.4.4. Reimbursement Framework
    • 9.8.4.5. UAE Topical Analgesics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 9.8.5. Kuwait
    • 9.8.5.1. Key Country Dynamics
    • 9.8.5.2. Target Disease Prevalence
    • 9.8.5.3. Regulatory Framework
    • 9.8.5.4. Reimbursement Framework
    • 9.8.5.5. Kuwait Topical Analgesics Market Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 10. Competitive Landscape

• 10.1. Participant Overview
• 10.2. Company Market Position Analysis
• 10.3. Company Categorization
• 10.4. Strategy Mapping
• 10.5. Company Profiles/Listing
  • 10.5.1. Haleon plc
    • 10.5.1.1. Overview
    • 10.5.1.2. Financial Performance
    • 10.5.1.3. Product Benchmarking
    • 10.5.1.4. Strategic Initiatives
  • 10.5.2. Hisamitsu Pharmaceutical Co., Inc.
    • 10.5.2.1. Overview
    • 10.5.2.2. Financial Performance
    • 10.5.2.3. Product Benchmarking
    • 10.5.2.4. Strategic Initiatives
  • 10.5.3. Kenvue Inc.
    • 10.5.3.1. Overview
    • 10.5.3.2. Financial Performance
    • 10.5.3.3. Product Benchmarking
    • 10.5.3.4. Strategic Initiatives
  • 10.5.4. Sanofi S.A.
    • 10.5.4.1. Overview
    • 10.5.4.2. Financial Performance
    • 10.5.4.3. Product Benchmarking
    • 10.5.4.4. Strategic Initiatives
  • 10.5.5. Viatris Inc.
    • 10.5.5.1. Overview
    • 10.5.5.2. Financial Performance
    • 10.5.5.3. Product Benchmarking
    • 10.5.5.4. Strategic Initiatives
  • 10.5.6. Teikoku Pharma USA, Inc.
    • 10.5.6.1. Overview
    • 10.5.6.2. Financial Performance
    • 10.5.6.3. Product Benchmarking
    • 10.5.6.4. Strategic Initiatives
  • 10.5.7. Perrigo Company plc
    • 10.5.7.1. Overview
    • 10.5.7.2. Financial Performance
    • 10.5.7.3. Product Benchmarking
    • 10.5.7.4. Strategic Initiatives
  • 10.5.8. Reckitt Benckiser Group plc.
    • 10.5.8.1. Overview
    • 10.5.8.2. Financial Performance
    • 10.5.8.3. Product Benchmarking
    • 10.5.8.4. Strategic Initiatives
  • 10.5.9. Advantice Health, LLC.
    • 10.5.9.1. Overview
    • 10.5.9.2. Financial Performance
    • 10.5.9.3. Product Benchmarking
    • 10.5.9.4. Strategic Initiatives
  • 10.5.10. Sun Pharmaceutical Industries Ltd.
    • 10.5.10.1. Overview
    • 10.5.10.2. Financial Performance
    • 10.5.10.3. Product Benchmarking
    • 10.5.10.4. Strategic Initiatives